Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report

G. Schifitto, D. R. Peterson, J. Zhong, H. Ni, K. Cruttenden, M. Gaugh, H. E. Gendelman, M. Boska, H. Gelbard

Research output: Contribution to journalArticle

66 Scopus citations

Abstract

In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.

Original languageEnglish (US)
Pages (from-to)919-921
Number of pages3
JournalNeurology
Volume66
Issue number6
DOIs
StatePublished - Mar 2006

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report'. Together they form a unique fingerprint.

  • Cite this

    Schifitto, G., Peterson, D. R., Zhong, J., Ni, H., Cruttenden, K., Gaugh, M., Gendelman, H. E., Boska, M., & Gelbard, H. (2006). Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report. Neurology, 66(6), 919-921. https://doi.org/10.1212/01.wnl.0000204294.28189.03